Topics

FORMA Therapeutics, Inc. Company Profile

04:28 EDT 16th September 2019 | BioPortfolio

FORMA Therapeutics is a privately-held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of transformative medicines that will make a difference for patients in need. A fully-integrated biopharmaceutical company, FORMA’s validated, proprietary R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create differentiated drug candidates with best-in-class or first-in-class potential. FORMA has delivered high-value clinical candidates to its partners and generated a broad proprietary portfolio of programs, ranging from pre-clinical to pivotal-stage, with the potential to provide profound patient benefit in hematologic, oncologic, and metabolic indications. For more information, please visit the company website at www.formatherapeutics.com.


News Articles [920 Associated News Articles listed on BioPortfolio]

Executives On The Move: Top Hires At FORMA And Synspira, And Perrigo Brings On New Finance Talent

Genentech SVP now CEO of cancer medicine developer FORMA Therapeutics and a new CEO also for cystic fibrosis treatment firm...   

AZ Explores Orphan Diseases To Boost Fasenra Growth

The company's severe asthma drug Fasenra has demonstrated its effectiveness in a Phase II trial for hypereosinophilic syndrome, a group...   

How to solve a key bottle neck in the drug discovery process

In December 2014 Domainex and ZoBio joined forces to deliver crucial drug target information to support FORMA Therapeutics’ Drug Discovery Programs. PharmaVentures' Adrian Dawkes caught up with Ed...

Are we on the verge of changing the way we treat cancer?

In the UK the majority of cancer research is funded through one funder, Cancer Research UKWith exclusive rights to over £300 million of cancer research per year Cancer Research Technology is a single...

DGAP-News: Immunic, Inc. veröffentlicht Finanzabschlüsse und Pro Forma-Finanzinformationen in Zusammenhang mit kürzlich abgeschlossener Aktientausch-Transaktion und stellt Unternehmens-Update bereit (deutsch)

Immunic, Inc. veröffentlicht Finanzabschlüsse und Pro Forma-Finanzinformationen in Zusammenhang mit kürzlich abgeschlossener Aktientausch-Transaktion und stellt Unternehmens-Update bereit DGAP-News...

Sarepta Therapeutics Acquires Myonexus Therapeutics For $165 Million

WASHINGTON (dpa-AFX) - Sarepta Therapeutics Inc. (SRPT), Wednesday said it has exercised its option to acquire Myonexus Therapeutics, a clinical-stage biotechnology company developing transformati...

Roche, Forma Cutting Jobs in Massachusetts

According to WARN notices, the two companies will slash a total of 106 jobs starting in March.

FORMA Therapeutics Announces Frank D. Lee as Chief Executive Officer

FORMA Therapeutics announced today the appointment of Frank D. Lee as Chief Executive Officer, starting on March 27, 2019. Frank succeeds Steve Tregay, Ph.D., who after more than ...

Drugs and Medications [30 Associated Drugs and Medications listed on BioPortfolio]

Forma-ray [gordon laboratories]

FORMA-RAY

Forma-ray [gordon laboratories]

FORMA-RAY

Kynamro [kastle therapeutics, llc]

NA

Olopatadine hydrochloride [somerset therapeutics, llc]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Vizumax hd [vizumax diagnostics llc]

These highlights do not include all the information needed to use, see full prescribing information for additional details. Initial U.S. Approval.

PubMed Articles [435 Associated PubMed Articles listed on BioPortfolio]

Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.

There is mounting evidence supporting the use of biologic therapeutics for the management of noninfectious uveitis (NIU). This review highlights: biologics with documented efficacy in NIU; agents with...

CRISPR: a promising tool for lipid physiology and therapeutics.

The purpose is to review recent progress in applying the CRISPR/Cas9 system to lipid metabolism and therapeutics.

Advancing Nucleic Acid Therapeutics by Setting Uniform Standards for Experimental Controls.

La cistitis enfisematosa es una forma complicada de infección urinaria, que se caracteriza por la presencia de aire dentro de la pared y en la luz de la vejiga, que afecta más a diabéticos, anciano...

Inclusion of a specific prompt within the standard clinical pro forma used in assessment of patients referred to a child and adolescent sexual assault treatment service: A suggested safety-net to facilitate detection of other children at risk of child sexual abuse.

Evaluation of an index case of child abuse necessitates risk assessment of other children who could be vulnerable to abuse from the same perpetrator/s.

Clinical Trials [188 Associated Clinical Trials listed on BioPortfolio]

RF Rejuvenation for Pelvic Floor and Vagina

Evaluation of efficacy and safety of the Votiva RF system with the Forma V handpiece for vaginal treatments.

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

Companies [1373 Associated Companies listed on BioPortfolio]

FORMA Therapeutics

FORMA Therapeutics unlocks intractable targets to create transformative small molecule therapies. The Company is achieving this by applying its proprietary cell-based screening, s...

FORMA Therapeutics, Inc.

FORMA Therapeutics is a privately-held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of transformative medicines that will make a difference fo...

FORMA Therapeutics Holdings, LLC

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

More Information about "FORMA Therapeutics, Inc." on BioPortfolio

We have published hundreds of FORMA Therapeutics, Inc. news stories on BioPortfolio along with dozens of FORMA Therapeutics, Inc. Clinical Trials and PubMed Articles about FORMA Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of FORMA Therapeutics, Inc. Companies in our database. You can also find out about relevant FORMA Therapeutics, Inc. Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks



Searches Linking to this Company Record